Abbott Labs finds $500 mil.
This article was originally published in The Gray Sheet
Executive Summary
Planned spin-off of hospital products company will free up about $500 mil. for Abbott to invest in development of remaining high-margin, high-growth businesses such as stents, spinal fusion systems and pharmaceuticals (1"The Gray Sheet" Aug. 25, 2003, p. 3). After transferring roughly $2.5 bil. in sales to the new company, Abbott will be left with a $16.8 bil. sales baseline, based on analysts' consensus 2003 revenue estimates. At that level, the 3% increase in gross margins projected by Abbott as a result of the spin-off (from the current 48% to 51%) translates into an extra $500 mil. in gross profit. Separately, Abbott notes that the beginning of its "pre-audit" is on track for year-end FDA inspections under its 1999 diagnostics consent decree...
You may also be interested in...
Abbott Sharpens Focus On Higher-Margin Products, Spins Off Hospital Unit
Abbott will refocus resources on advanced technologies including stents and spinal fusion systems after divesting the lion's share of its slower-growth hospital products unit in a spin-off to shareholders
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.